Free Trial
→ Washington Is Broke—and Eyeing Your Savings Next (From Priority Gold) (Ad)

Will the Biotech sector sustain its momentum in 2024?

Ryan Hasson
Written by Ryan Hasson | Reviewed by Don Miller
January 4, 2024

Key Points

  • Biotech's iShares ETF (IBB) experienced a near 4% upswing on the year's first trading day, outshining struggling sectors.
  • The IBB ETF now faces critical resistance at $138 after a robust three-month climb.
  • AMGN, VRTX, and GILD, the top holdings in the ETF, significantly impact the sector's direction based on their individual performances.
  • Five stocks we like better than iShares Biotechnology ETF.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in iShares Biotechnology ETF Right Now?

Before you consider iShares Biotechnology ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iShares Biotechnology ETF wasn't on the list.

While iShares Biotechnology ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover
A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Learn More about Ryan Hasson
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.6235 of 5 stars		$275.01-0.3%3.46%36.43Hold$309.22
Gilead Sciences (GILD)
4.6956 of 5 stars		$109.11+2.8%2.90%294.89Moderate Buy$110.55
Vertex Pharmaceuticals (VRTX)
4.6624 of 5 stars		$447.18+1.5%N/A-203.26Moderate Buy$515.04
iShares Biotechnology ETF (IBB)N/A$124.67+1.8%0.30%23.96Moderate Buy$124.67
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs
New AI Deals Just Sent These 4 Infrastructure Stocks Soaring

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines